Clinical trial
A Phase 2 Study to Evaluate the Safety and Biologic Activity of APL- 2 in Patients With IgA Nephropathy, Lupus Nephritis, Primary Membranous Nephropathy, or C3 Glomerulopathy (C3 Glomerulonephritis and Dense Deposit Disease)
NCT03453619 is registered in ClinicalTrials.gov with Apellis Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study to Evaluate the Safety and Biologic Activity of APL- 2 in Patients With IgA Nephropathy, Lupus Nephritis, Primary Membranous Nephropathy, or C3 Glomerulopathy (C3 Glomerulonephritis and Dense Deposit Disease)
- Lead sponsor
- Apellis Pharmaceuticals, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 26, 2018
- Completion date
- August 26, 2023
- Enrollment
- 21 (actual)
- Sites
- 17
Conditions
As the registry lists them; a condition with its own page is linked.
c3 glomerulonephritis, dense deposit disease, iga nephropathy, lupus nephritis, membranous nephropathy